Saturday 17 October 2026
Export CTKB’s income statement to Excel — free account
Cytek Biosciences, Inc.
CTKB Healthcare Medical Devices
Cytek Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $201.5 million, up 0.52% from fiscal 2024. In the quarter to June 2026, revenue grew 5.57%, EPS fell 125.0%, free cash flow grew 42.5% and total debt fell 68.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
5.24
0.17
−3.14%
Follow CTKB
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.25 | 3.20 | 2.75 | 2.77 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(113.54) | (836.73) | (205.57) | 419.54 | |
P/B ratio |
1.17 | 1.89 | 1.72 | 1.78 | |
Price to Tangible BV |
1.29 | 2.09 | 1.91 | 1.97 | |
EV/Sales |
0.92 | 1.91 | 1.47 | 1.51 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(94.64) | (81.97) | (41.20) | (51.63) | |
EV/FCF |
(31.68) | (44.54) | (23.83) | (26.05) | |
Quick Ratio |
4.23 | 4.16 | 3.88 | 3.70 | |
Current Ratio |
5.17 | 5.04 | 4.69 | 4.48 | |
Net Debt/EBITDA |
42.58 | 102.35 | 16.73 | 31.11 | |
Debt/Assets |
0.13% | 0.11% | 0.09% | 0.06% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.40 | 0.42 | 0.44 | 0.44 | |
Operating CF/Net income |
0.71 | 0.02 | 0.15 | (0.11) | |
Capex/Depreciation |
(0.21) | (0.28) | (0.78) | (0.75) | |
Interest Coverage |
(18.61) | 7.71 | (70.47) | (40.57) | |
Research and Development Expense of Revenue |
17.13% | 14.42% | 21.76% | 20.23% | |
Selling, General and Administrative Expense of Revenue |
53.14% | 47.50% | 68.23% | 62.32% | |
Intangible Assets out of Total Assets |
0.07 | 0.07 | 0.07 | 0.07 | |
Share Based Compensation of Revenue |
10.78% | 8.89% | 11.01% | 11.09% | |
Graham Net Nets |
0.61 | 0.42 | 0.46 | 0.44 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.88%) | (10.10%) | (13.04%) | (14.00%) | |
Free Cash Flow Yield |
(1.29%) | (1.34%) | (2.24%) | (2.09%) | |
Revenue per Share |
0.41 | 0.49 | 0.34 | 0.37 | |
Operating CF per Share |
(0.03) | (0.01) | (0.02) | 0.01 | |
Capex per Share |
(0.01) | (0.01) | (0.02) | (0.02) | |
Free Cash Flow per Share |
(0.04) | (0.01) | (0.04) | (0.01) | |
Cash per Share |
2.05 | 2.05 | 2.04 | 2.02 | |
Shareholders Equity per Share |
2.97 | 2.68 | 2.55 | 2.49 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.97 | 2.68 | 2.55 | 2.49 | |
Free Cash Flow |
(4.55) | (1.61) | (4.93) | (0.87) | |
Working Capital |
313.28 | 314.19 | 298.37 | 293.60 | |
Capital Expenditures |
(0.65) | (0.84) | (2.19) | (2.24) | |
Net Current Asset Value |
272.14 | 272.19 | 257.83 | 252.95 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.01 | 0.05 | 0.05 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
54.63 | 61.55 | 53.47 | 52.97 | |
Average Payables |
6.51 | 5.97 | 6.49 | 7.63 | |
Average Inventory |
49.22 | 46.16 | 47.57 | 50.87 | |
Average Assets |
493.07 | 480.52 | 465.85 | 470.13 | |
Average Common Equity |
382.02 | 368.74 | 353.63 | 349.76 |
Columns are period end dates